Addendum

Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86

Status
Status: Commission completed
Project no.
A24-07
Last updated

Report documents

  1. Addendum

    Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86

    published on
    Document type
    PDF document, 2 MB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-07_en

Dossier assessment

Indication:

Adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least 2 additional systemic therapies in the advanced setting

Result of dossier assessment:

After addendum now: proof of considerable added benefit

Additional information

Federal Joint Committee (G-BA)

2024-02-15 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A24-07
Commission
Commission awarded on 09.01.2024 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://dx.doi.org/10.60584/A24-07_en

Connected Projects

  1. Dossier assessment

    Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-86
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-95
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form